Filing Flows › Spruce Biosciences (SPRB) › Who owns the stock
Who owns Spruce Biosciences (SPRB) stock
63 funds reported Spruce Biosciences (SPRB) shares in their latest 13F filings, worth $108M in all. The largest holder is Aigh Capital Management LLC ($12.1M). Last quarter 42 funds added to their stakes and 12 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Aigh Capital Management LLC | 250,000 | $12.1M | unchanged | 2026-09-30 |
| Orbimed Advisors LLC | 200,000 | $10.8M | new | 2026-06-30 |
| BlackRock | 187,836 | $10.1M | increase | 2026-06-30 |
| Millennium Management LLC | 160,981 | $8.7M | increase | 2026-06-30 |
| Ikarian Capital, LLC | 121,356 | $6.6M | unchanged | 2026-06-30 |
| Vanguard Capital Management LLC | 119,331 | $6.4M | increase | 2026-06-30 |
| Alyeska Investment Group, L.P. | 81,671 | $4.4M | increase | 2026-06-30 |
| Geode Capital Management, LLC | 70,548 | $3.8M | increase | 2026-06-30 |
| ADAR1 Capital Management, LLC | 67,717 | $3.7M | increase | 2026-06-30 |
| Cable Car Capital, LP | 60,000 | $3.2M | new | 2026-06-30 |
| Citadel Advisors LLC | 51,905 | $2.8M | decrease | 2026-06-30 |
| State Street | 50,450 | $2.7M | increase | 2026-06-30 |
| Boothbay Fund Management, LLC | 42,080 | $2.3M | unchanged | 2026-06-30 |
| Stempoint Capital LP | 41,388 | $2.2M | increase | 2026-06-30 |
| Eversept Partners, LP | 40,000 | $2.2M | new | 2026-06-30 |
Spruce Biosciences' latest quarter
Spruce Biosciences, Q4 2024: revenue $697K (-76% year over year), net loss $23.6M, operating cash flow −$20.7M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most SPRB stock?
By the latest 13F filings: Aigh Capital Management LLC ($12.1M); Orbimed Advisors LLC ($10.8M); BlackRock ($10.1M); Millennium Management LLC ($8.7M); Ikarian Capital, LLC ($6.6M).
What is the short interest in SPRB?
522,120 shares were sold short at the 2026-10-15 settlement, 20.99% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.